European healthtech and medtech sectors embrace industrialisation with increased M&A activity in 2026

The European HealthTech and MedTech sectors enter 2026 under a single, decisive theme: industrialisation. What began as a period of venture-backed experimentation has crystallised into a phase in which scale, regulatory resilience and operational platforms determine value. The result will be a targeted wave of consolidation that is as much about survival and compliance as it is about growth and market share. Below is a sector-by-sector synthesis of which sub-sectors are most likely to see meaningful M&A activity during 2026, and why.

Regulatory and financial context
The twin pressures of tightened regulation and an overhang of private capital are the primary drivers compressing deal flow toward fewer, larger winners. Industry groups have been vocal: MedTech Europe urged the European Commission to ease near-term re‑certification burdens to avoid a certification bottleneck, a plea reported by MedTech Dive. At the same time, the European Commission’s Digital Omnibus package, unveiled in November 2025, offers conditional extensions to compliance timelines for certain high‑risk AI systems and proposes staged application dates tied to harmonised standards, according to legal analysis by Schoenherr. These regulatory moves moderate, but do not remove, the compliance cost curve created by the EU Medical Device Regulation (MDR), In Vitro Diagnostic Regulation (IVDR) and the EU AI Act.

Financially, private equity remains a force. Market analysis published earlier in 2025 documented a large increase in buyout activity in European healthcare, and private capital now seeks platforms that can absorb add‑ons and deliver predictable cashflow. That combination of regulatory friction and “dry powder” will favour acquirers with deep regulatory teams and access to capital, while pressuring undercapitalised SMEs toward sale or strategic partnership.

High-probability consolidation targets in 2026

1. Outpatient services and clinic chains (dental, ophthalmology, fertility, specialist outpatient surgery)
   Why: Fragmentation plus capital intensity. Dental and ophthalmology services require heavy upfront investment in digital workflows and specialised equipment; fertility clinics require centralised embryology labs and marketing scale. Private equity buy‑and‑build models remain well suited to these markets because operational standardisation and procurement leverage materially improve unit economics. Healthcare.digital has repeatedly highlighted the migration of consolidation activity from mature markets (UK, Nordics) into Southern and Eastern Europe, where entry multiples remain attractive.

Where: Southern and Eastern Europe for roll‑ups; continued secondary buyouts and platform mergers in the UK, Benelux and DACH as the market matures.

2. Tech‑enabled home care and “hospital‑at‑home” platforms
   Why: Health systems are shifting care out of hospitals to manage capacity and costs. Tech‑enabled home care providers that combine agency networks with proprietary scheduling, remote monitoring and predictive analytics offer immediate savings and scalable margins. Case examples presented in market coverage show roll‑ups that overlay SaaS and AI to convert low‑margin analogue agencies into higher‑margin platforms.

Where: UK and Germany will be early staging grounds given policy pushes such as NHS Virtual Wards and ageing populations; pan‑European roll‑outs will follow.

3. Radiology and imaging networks (including teleradiology)
   Why: Capital intensity for scanners and the parallel need to integrate AI tools create a classic consolidation play. Large imaging groups can amortise hardware spend, deploy centralised AI and teleradiology hubs to solve workforce shortages, and capture higher pricing power. OEMs and large imaging chains will also pursue strategic acquisitions to bundle AI into equipment and PACS offerings.

Where: Cross‑border platforms expanding from France and Germany into Benelux, Italy and Southern Europe.

4. Digital pathology and multimodal diagnostic platforms
   Why: Digital pathology is entering its industrialisation phase. Buyers, both scanner OEMs and large laboratory chains, seek vertically integrated “scan‑and‑analyse” solutions that reduce integration friction for community labs. The shift from single‑disease AI tools to multimodal foundation models increases the value of incumbents that can combine slide imaging, AI and genomics.

Where: Northern and Western Europe initially, with commercial roll‑outs into wider Europe as regulatory approvals for AI in primary diagnosis become more common.

5. AI‑enabled radiology and clinical AI vendors
   Why: The AI Act’s classification of many medical AI tools as “high‑risk” elevates compliance and data governance to financial assets. Startups with GDPR‑compliant datasets, clinical evidence and robust post‑market surveillance will command premium valuations or be strategic takeovers for OEMs seeking to create a “single pane” clinical platform. Conversely, non‑compliant point solutions face distress sales.

Where: Targets concentrated in innovation hubs (France, Israel, DACH) with acquirers including major OEMs and pan‑European hospital groups.

6. Contract Development and Manufacturing Organisations (CDMOs) specialising in complex biologics
   Why: Geopolitical supply‑chain rebalancing and the “friend‑shoring” trend favour European CDMOs with capabilities in viral vectors, ADCs and sterile fill–finish. Buyers seek to assemble specialised networks rather than generalist one‑stops to capture higher margins and mitigate sourcing risk.

Where: Western and Central Europe; strong interest from US PE and strategics seeking supply‑chain sovereignty.

7. Veterinary services in Continental Europe
   Why: While the UK and Nordics have seen earlier consolidation, regulatory scrutiny in the UK (Competition and Markets Authority) and workforce shortages are pushing investors toward Continental markets where corporate ownership is lower and roll‑up potential remains significant. Acquirers that can solve recruitment and retention through centralised HR, visa support and clinical career pathways will be advantaged.

Where: France, Germany, Italy and Southern Europe.

8. Digital therapeutics and DiGA‑adjacent platforms
   Why: Germany’s DiGA reimbursement pathway has matured the market, creating pressure toward platformisation. Single‑indication apps will struggle; consolidations that create multi‑indication or comorbidity platforms are the more likely path to scale. Reimbursement requirements and interoperability under the emerging European Health Data Space favour larger, better‑capitalised players.

Where: Germany as the nucleus, with cross‑border consolidation into the Nordics and DACH.

Deal structures and friction points
Expect creative financing and contingent pricing to bridge valuation gaps. Earn‑outs, founder rollovers and vendor financing will be common, particularly where uncertainty around near‑term revenue persists. Continuation funds will enable PE sponsors to retain high‑performing platforms and deploy additional capital for add‑ons rather than forcing exits into a thin IPO market, reinforcing the industrialisation thesis.

At the same time, regulatory relief or delay could alter timelines. MedTech Europe’s call for postponement of certain re‑certification requirements (reported by MedTech Dive) and the conditional extensions included in the Digital Omnibus (reported by Schoenherr) may alleviate immediate pressure on some SMEs and slow fire‑sale scenarios in 2026. Nevertheless, the underlying economics of scale, data sovereignty and the cost of compliance will continue to concentrate value in consolidated platforms.

Regional nuances

• UK: active in social care, specialty clinics and home‑care technologies; regulatory divergence and CMA scrutiny remain salient risks.
• DACH: a hub for digital therapeutics and a testing ground for DiGA‑driven consolidation.
• France: policy support for national champions and active antitrust oversight will shape deal forms.
• Southern & Eastern Europe: primary arenas for PE roll‑ups in dental, vet and outpatient services owing to lower entry multiples and growth leverage.
• Benelux: advanced, consolidated market functioning as a laboratory for integrated care models.

Conclusion
In 2026 the European HealthTech and MedTech ecosystem will not undergo indiscriminate M&A; it will rationalise. The most likely consolidation candidates are those where scale lowers unit costs, regulatory capabilities unlock market access, or platformisation converts fragmented point solutions into integrated care workflows. Services that can be standardised and tech‑enabled, dental, ophthalmology, fertility, radiology, veterinary and home care, are prime targets for buy‑and‑build plays. On the tech side, AI‑enabled diagnostics, digital pathology, and SaaS platforms that provide the operating system for decentralised care will attract strategic buyers and deep‑pocketed PE. Regulation and capital availability will shape timing and structure, but the direction is clear: the sector is moving from laboratories of experimentation to factories of repeatable, scalable healthcare delivery.